Investigational COVID-19 vaccine well-tolerated and generates immune response in older adults.

[2greys]

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19 disease.

The experimental vaccine, mRNA-1273, was co-developed by researchers at NIAID and Moderna, Inc. of Cambridge, Massachusetts. The Phase 1 trial began on March 16, 2020, and was expanded to enroll older adults about one month later. Older adults are more vulnerable to complications of COVID-19 and are an important population for vaccination. Understanding how the vaccine affects older adults is a critical part of measuring its safety and efficacy.

nih.gov/news-events/news-re...

The New England Journal of Medicine. Research Paper:

nejm.org/doi/10.1056/NEJMoa...

[PurpleAlf]

This sounds very positive. Thank you

[Patk1]

Thanku!

[MoyB]

Could there be light at the end of the tunnel? Very interesting 2greys and gives us some hope. xx Moy

[Trishe]

This sounds great, but I don't think I would like to have it just yet, I'd rather wait until it's definitely safe for us with already compromised lungs.

[INK45]

I can understand that elderly people may be taken in and feel safer and shielded if they get jabbed over and over, but what about the children? What are your thoughts about injecting young kids, even newborns, with this Emergency Use Authorisation (EUA) concoction?

This is an interesting article from Nesweek; childrenshealthdefense.org/...